Almirall and Forest announce positive results from the ACCORD COPD I Phase III study of aclidinium bromide in Chronic Obstructive Pulmonary Disease (COPD)

· Top line results of ACCORD COPD I, the first three-month Phase III pivotal study with aclidinium twice daily (BID) in patients with COPD, met primary endpoint [1] .

The release as fetched from its publisher. almirall.com ↗